Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb


UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e Peak Sales NPV
Core Products                  
Cimzia 1,712 1,797 1,869 1,932 1,926 1,768 1,517   5,120
Vimpat 1,322 1,446 1,528 1,366 865 681 555   2,812
Keppra  770 768 715 647 592 545 498   2,216
Briviact 221 291 356 424 486 540 579 621 1,687
Neupro 319 309 267 223 191 164 141   572
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   390  567 723 866 997 1,097 1,357 2,158
Nayzilam   24 46 67 90 109 120 157 368
Bimekizumab   0 99 366 702 1,062 1,456  2,630  5,338
Zilucoplan   0 0 32 153 323 502 1,133 2,003
Rozanolixizumab    0 0 9 78 201 364 1,086 1,606
Dapimab   0 7 16 34 64 108    
Staccato alprazolam   0 0 1 4 28 80 270  399 
UCB0107 (Anti-Tau)   0 0 0 11 70 130    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,022 5,281 5,439 5,361
Revenue  4,913 5,244 5,488 5,641 5,556
Adjusted EBIT 1,118  1,101 1,229 1,402 1,376
Adjusted EBITDA 1,431  1,441 1,585 1,755 1,738
Net Profit*  792 721 884 1,042 1,027
Core EPS (€) 5.20  4.93 5.55 6.36 6.32

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e Peak Sales NPV
Core Products                  
Cimzia 1,712 1,792 1,869 1,954 1,935 1,804 1,509   5,112
Vimpat 1,322 1,444 1,508 1,410 877 689 540   2,723
Keppra 770 777 709 638 591 540 490   2,127
Briviact 221 291 347 412 472 525 579 605 1,649
Neupro 319 306 277 218 189 165 140   583
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   376 584 692 851 1,010 1,133 1,329 2,093
Nayzilam   25 47 68 89 109 116 150 399
Bimekizumab   0 84 370 717 1,076 1,431 2,618 5,235
Zilucoplan   0 0 0 146 320 470 1,116 2,030
Rozanolixizumab (Rozimab)   0 0 0 81 175 375 1,000 1,465
Dapimab   0 0 0 0 25 50    
Staccato alprazolam   0 0 0 0 24 69  200 435 
UCB0107 (Anti-Tau)   0 0 0 0 63 102    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,017 5,283  5,481  5,385
Revenue  4,913 5,239 5,484 5,699 5,565
Adjusted EBIT 1,118  1,079 1,231 1,400 1,456
Adjusted EBITDA 1,431 1,428 1,579 1,789 1,816
Net Profit*  792  722 875 1,027 1,027
Core EPS (€) 5.20 4.90 5.51 6.27
6.41

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 08 February 2021



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.